Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2962 · 1 trial · 1 indication
A DLT is defined as an adverse event or abnormal laboratory value occurring during the DLT-evaluation period (first 28 days of treatment). This will be evaluated to assess the safety and tolerability and also to identify optimal biological dose (OBD) of AZD2962.
To assess the safety and tolerability of AZD2962 and also to identify OBD of AZD2962.
To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.
To assess the safety and tolerability of AZD2962, and also to identify OBD of AZD2962.
| Arm | Type | Description |
|---|---|---|
| Module 1- AZD2962 (Monotherapy) | EXPERIMENTAL | Participants with MDS and dysplastic CMML will receive AZD2962 as monotherapy in a dose escalation pattern. |
| Name | Type | Description |
|---|---|---|
| AZD2962 | DRUG | AZD2962 will be administered orally once daily. |
Key Inclusion Criteria: 1. Participants with relapsed/refractory MDS or participants with relapsed/refractory dysplastic CMML, with peripheral blasts or bone marrow blasts \< 20%, and who received one or more prior lines of therapy as per standard of care (or who exhausted locally available treatme...
AZD2962 is an investigational small molecule being studied for the treatment of haematologic neoplasms, which are blood cancers. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD2962 is an IRAK4 inhibitor, meaning it targets and blocks the activity of IRAK4, a body protein involved in inflammatory and immune responses. By inhibiting IRAK4, the drug aims to interfere with pathways that may contribute to the growth of blood cancers.
AZD2962 is being developed by AstraZeneca PLC, a global biopharmaceutical company. AstraZeneca's stock is traded under the ticker symbol AZN on major stock exchanges.
AZD2962 is in Phase 1 clinical development. It is an investigational drug, meaning it is still being tested in clinical trials and has not yet been approved for use in patients.
AZD2962 is being studied in a Phase 1 clinical trial with the identifier NCT07064122. This trial is currently recruiting participants and aims to enroll 72 patients with haematologic neoplasms. The study is being conducted in the United States, Australia, Japan, South Korea, Spain, Taiwan, and the United Kingdom.
AZD2962 is an IRAK4 inhibitor, but it is not the same as other IRAK4 inhibitors. It is a specific drug candidate developed by AstraZeneca, and its unique chemical structure and properties distinguish it from other drugs in the same class.